{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T21:02:29Z","timestamp":1792357349259,"version":"4.4.0"},"reference-count":25,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[1999,5]]},"abstract":"<jats:p> PURPOSE: To eliminate the risk of rejection and lower the risk of relapse after T-cell\u2013depleted bone marrow transplants in acute leukemia patients, we enhanced pretransplant immunosuppression and myeloablation. <\/jats:p><jats:p> PATIENTS AND METHODS: Antithymocyte globulin and thiotepa were added to standard total-body irradiation\/cyclophosphamide conditioning. Donor bone marrows were depleted ex vivo of T lymphocytes by soybean agglutination and E-rosetting. This approach was tested in 54 consecutive patients with acute leukemia who received transplants from HLA-identical sibling donors or, in two cases, from family donors mismatched at D-DR. No posttransplant immunosuppressive treatment was given as graft-versus-host disease (GVHD) prophylaxis. <\/jats:p><jats:p> RESULTS: Neither graft rejection nor GVHD occurred. Transplant-related deaths occurred in six (16.6%) of 36 patients in remission and in seven (38.8%) of 18 patients in relapse at the time of transplantation. The probability of relapse was .12 (95% confidence interval [CI], 0 to .19) for patients with acute myeloid leukemia and .28 (95% CI, .05 to .51) for patients with acute lymphoblastic leukemia who received transplants at the first or second remission. At a median follow-up of 6.9 years (minimum follow-up, 4.9 years), event-free survival for patients who received transplants while in remission was .74 (95% CI, .54 to .93) for acute myeloid leukemia patients and .59 (95% CI, .35 to .82) for acute lymphoblastic leukemia patients. All surviving patients have 100% performance status. <\/jats:p><jats:p> CONCLUSION: Adding antithymocyte globulin and thiotepa to the conditioning regimen prevents rejection of extensively T-cell\u2013depleted bone marrow. Even in the complete absence of GVHD, the leukemia relapse rate is not higher than in unmanipulated transplants. <\/jats:p>","DOI":"10.1200\/jco.1999.17.5.1545","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T10:08:12Z","timestamp":1487930892000},"page":"1545-1545","source":"Crossref","is-referenced-by-count":83,"title":["Improved Outcome With T-Cell\u2013Depleted Bone Marrow Transplantation for Acute Leukemia"],"prefix":"10.1200","volume":"17","author":[{"given":"Franco","family":"Aversa","sequence":"first","affiliation":[{"name":"From the BMT Program, Section of Hematology and Clinical Immunology, University of Perugia, Perugia, Italy; and Department of Immunology, Weizmann Institute of Science, Rehovot, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adelmo","family":"Terenzi","sequence":"additional","affiliation":[{"name":"From the BMT Program, Section of Hematology and Clinical Immunology, University of Perugia, Perugia, Italy; and Department of Immunology, Weizmann Institute of Science, Rehovot, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Carotti","sequence":"additional","affiliation":[{"name":"From the BMT Program, Section of Hematology and Clinical Immunology, University of Perugia, Perugia, Italy; and Department of Immunology, Weizmann Institute of Science, Rehovot, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Felicini","sequence":"additional","affiliation":[{"name":"From the BMT Program, Section of Hematology and Clinical Immunology, University of Perugia, Perugia, Italy; and Department of Immunology, Weizmann Institute of Science, Rehovot, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Jacucci","sequence":"additional","affiliation":[{"name":"From the BMT Program, Section of Hematology and Clinical Immunology, University of Perugia, Perugia, Italy; and Department of Immunology, Weizmann Institute of Science, Rehovot, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Zei","sequence":"additional","affiliation":[{"name":"From the BMT Program, Section of Hematology and Clinical Immunology, University of Perugia, Perugia, Italy; and Department of Immunology, Weizmann Institute of Science, Rehovot, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Latini","sequence":"additional","affiliation":[{"name":"From the BMT Program, Section of Hematology and Clinical Immunology, University of Perugia, Perugia, Italy; and Department of Immunology, Weizmann Institute of Science, Rehovot, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Aristei","sequence":"additional","affiliation":[{"name":"From the BMT Program, Section of Hematology and Clinical Immunology, University of Perugia, Perugia, Italy; and Department of Immunology, Weizmann Institute of Science, Rehovot, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Santucci","sequence":"additional","affiliation":[{"name":"From the BMT Program, Section of Hematology and Clinical Immunology, University of Perugia, Perugia, Italy; and Department of Immunology, Weizmann Institute of Science, Rehovot, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Paola","family":"Martelli","sequence":"additional","affiliation":[{"name":"From the BMT Program, Section of Hematology and Clinical Immunology, University of Perugia, Perugia, Italy; and Department of Immunology, Weizmann Institute of Science, Rehovot, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Cunningham","sequence":"additional","affiliation":[{"name":"From the BMT Program, Section of Hematology and Clinical Immunology, University of Perugia, Perugia, Italy; and Department of Immunology, Weizmann Institute of Science, Rehovot, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yair","family":"Reisner","sequence":"additional","affiliation":[{"name":"From the BMT Program, Section of Hematology and Clinical Immunology, University of Perugia, Perugia, Italy; and Department of Immunology, Weizmann Institute of Science, Rehovot, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo F.","family":"Martelli","sequence":"additional","affiliation":[{"name":"From the BMT Program, Section of Hematology and Clinical Immunology, University of Perugia, Perugia, Italy; and Department of Immunology, Weizmann Institute of Science, Rehovot, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1-1545","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V78.8.2120.2120"},{"key":"R2-1545","unstructured":"Martin  PJ,  Hansen  JA,  Torok-Storb  B, et al: Graft failure in patients receiving T-cell-depleted HLA-identical allogeneic marrow transplants.  Bone Marrow Transplant 3:445,1988-456,"},{"key":"R3-1545","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-108-6-806"},{"key":"R4-1545","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V74.6.2227.2227"},{"key":"R7-1545","doi-asserted-by":"crossref","unstructured":"Gale  RP,  Reisner  Y: Graft rejection and graft versus host disease: A mirror image.  Lancet 1:1468,1986-1470,","DOI":"10.1016\/S0140-6736(86)91503-5"},{"key":"R8-1545","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199010000-00040"},{"key":"R9-1545","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(83)90412-1"},{"key":"R10-1545","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-198609000-00019"},{"key":"R11-1545","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-197410000-00001"},{"key":"R12-1545","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V68.2.378.378"},{"key":"R13-1545","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"R15-1545","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V79.12.3380.3380"},{"key":"R16-1545","unstructured":"Aversa  F,  Pelicci  PG,  Terenzi  A, et al: Results of T-depleted BMT in chronic myelogenous leukaemia after a conditioning regimen that included thiotepa.  Bone Marrow Transplant 7:24,1991,  (suppl 2)"},{"key":"R17-1545","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.3.1083"},{"key":"R18-1545","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V70.5.1692.1692"},{"key":"R19-1545","unstructured":"Schouten  HC,  Sizoo  W,  Van't Veer  MB, et al: Incomplete chimerism in erythroid, myeloid and B lymphocyte lineage after T-cell-depleted allogeneic bone marrow transplantation.  Bone Marrow Transplant 3:407,1988-412,"},{"key":"R20-1545","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V66.3.664.664"},{"key":"R21-1545","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.8.3079.3079_3079_3083"},{"key":"R22-1545","unstructured":"Marmont  AM,  Gale  RP,  Butturini  A, et al: Forum: T-cell depletion in allogeneic bone marrow transplantation: Progress and problems.  Haematologica 74:235,1989-248,"},{"key":"R23-1545","unstructured":"Weiss  L,  Reich  S,  Slavin  S: Effect of cyclosporine A and methylprednisolone on the graft-versus-leukemia effects across major histocompatibility barriers in mice following allogeneic bone marrow transplantation.  Bone Marrow Transplant 6:229,1990-233,"},{"key":"R24-1545","doi-asserted-by":"crossref","unstructured":"Cox  DR: Regression models and life tables.  J R Stat Soc 34:187,1972-220,","DOI":"10.1111\/j.2517-6161.1972.tb00899.x"},{"key":"R25-1545","unstructured":"Geller  RB,  Myers  S,  Devine  S, et al: Phase I study of busulfan, cyclophosphamide, and timed sequential escalating doses of cytarabine followed by bone marrow transplantation.  Bone Marrow Transplant 9:41,1992-47,"},{"key":"R26-1545","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(90)90253-G"},{"key":"R27-1545","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V76.9.1867.1867"},{"key":"R28-1545","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199812033392301"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.1999.17.5.1545","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T22:18:51Z","timestamp":1653517131000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.1999.17.5.1545"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,5]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1999,5]]}},"alternative-id":["10.1200\/JCO.1999.17.5.1545"],"URL":"https:\/\/doi.org\/10.1200\/jco.1999.17.5.1545","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,5]]}}}